메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Hiroyuki Shimada (Department of Pathology and Pediatrics Stanford University School of Medicine Stanford CA USA) Hideki Sano (Department of Pathology Oncology Fukushima Medical University Hospital Fukushima Japan) Florette K. Hazard (Department of Pathology and Pediatrics Stanford University School of Medicine Stanford CA USA)
저널정보
대한소아혈액종양학회 Clinical Pediatric Hematology-Oncology Clinical Pediatric Hematology-Oncology Vol.27 No.2
발행연도
2020.1
수록면
73 - 86 (14page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Peripheral neuroblastic tumors (pNTs including Neuroblastoma, Ganglioneuroblastoma and Ganglioneuroma) are biologically and clinically heterogeneous. In order to develop efficient clinical treatment protocols of this disease, patients are stratified into different risk groups based on the combination of so-called prognostic factors. In this review, the prognostic factors are classified as clinically defined (Clinical staging and Age at diagnosis), histopathologically defined [International Neuroblastoma Pathology Classification (INPC) distinguishing Favorable Histology (FH) Group and Unfavorable Histology (UH) Group] and genetically/molecularly defined [MYCN oncogene amplification, DNA index, Segmental chromosomal aberrations, ALK (Anaplastic Lymphoma Kinase) mutation/amplification and Abnormal maintenance/elongation of telomeres], are outlined. According to the Children’s Oncology Group (COG) Neuroblastoma studies, the survival rate of patients in low- or intermediate-risk group is more than 90%. In contrast, the survival rate of patients in the high-risk group remains less than 50% despite currently available high-intensity and multimodal therapy. As described in the genetically/molecularly defined prognostic factors, tumors in the high-risk group, majority of which are classified into the UH group according to the INPC, are molecularly heterogeneous. Based on the recent progress of precision medicine along with our correlative analyses between molecular alterations and their morphological manifestations, four subgroups; i.e., MYC subgroup, TERT subgroup, ALT subgroup and Null subgroup, are identified immunohistochemically in the UH group for future management of the patients with this unique d isease.

목차

등록된 정보가 없습니다.

참고문헌 (78)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0